TYRA appoints urologic oncologist, Erik Goluboff, M.D., as SVP, Clinical Development to lead NMIBC--First patient expected to be dosed in SURF302 in Q2 2025-CARLSBAD, CA, USA I J ...
Pascal Siakam scored 25 points and grabbed 11 rebounds to help the Pacers escape against an undermanned but motivated ...
Precision BioSciences gains momentum as iECURE reports positive ECUR-506 data, and analysts forecast significant HBV ...
Hosted on MSN1d
BMO Capital Upgrades Precision BioSciences (DTIL)Fintel reports that on January 10, 2025, BMO Capital upgraded their outlook for Precision BioSciences (NasdaqCM:DTIL) from ...
Precision BioSciences (NASDAQ:DTIL) added ~26% in the morning hours on Friday after the gene-editing company said ECUR-506, ...
Is it just market speculation, or is there something more significant unfolding behind the scenes? At the core of Precision BioSciences’ sudden stock surge is the company’s gene-editing technology, ...
JonesTrading analyst Soumit Roy maintained a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a price target of ...
Character Biosciences Announces Collaboration with Bausch + Lomb to Transform Ophthalmology with Precision Medicine ...
1d
BMO Capital analyst Kostas Biliouris upgraded the rating on Precision BioSciences (DTIL – Research Report) to a Buy today, setting a price ...
The funding will be used to move the ARGO-HT research platform into an FDA-cleared system to support the development of diagnostic tests.
About Cogent Biosciences, Inc. Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback